Close
Open Nav
Why Attend GreenTech Investor Sessions?

The BIO GreenTech Investor Sessions provide high visibility to early stage emerging industrial biotechnology companies to present in front of VC investors, analysts, angel investors, and strategists. No other GreenTech private equity industrial biotechnology conference is designed with the latest innovation in mind, offering networking and high quality content while creating partnerships and new business opportunities. During the BIO GreenTech Investor Sessions, emerging companies covering advanced biofuels and renewable chemical platforms will share their new technologies and value proposition through formal 15-minute presentations to an elite audience of investors* and analysts.

Investor Panel : The investor panel is comprised of an international group of leading investors who will discuss investment opportunities and trends in GreenTech. The panel will take place on Monday, July 24 from 9:30am - 10:10am. 

Moderator Panelists
   

Roger Wyse
Managing Partner
Spruce Capital Partners

Brian Baynes
Partner
Flagship Pioneering
Jason Webber
Principal
Sustainable Conversion Ventures
Emily Landsburg
Director
Ultra Capital
       
 
  Shaun Healy
Senior Ventures Associate
BP Ventures
Ganesh Kishore
Managing Partner
Spruce Capital Partners
Felipe Pereira
Chemical Sector Manager
Brazilian National Development Bank (BNDES)



Innovative companies were selected to participate in this program based on the following criteria:

•    Breakthrough clean technologies
•    Bio-based consumer product strategies
•    Proof of concept
•    Extensive intellectual property coverage

 

Networking Opportunity 

  • Connecting with the right people is essential for building relationships and organizing deals 
  • The BIO One-on-One Partnering™ system provides industrial biotechnology companies with the opportunity to schedule private meetings with investors, and industry business development and licensing executives
  • The GreenTech Investor Sessions brings the right people together, while ensuring there is a pleasant mix of industrial biotechnology attendees and a low percentage of service providers

High Quality Content

  • An elite group of private and early stage emerging industrial biotechnology companies will present their new technologies, accomplishments, value propositions, business case, and exit strategies during the BIO GreenTech Investor Sessions
  • The BIO GreenTech Investor Sessions provide an opportunity for investors to learn about the latest technologies and connect with executives from innovative companies
  • A panel discussion by leading investment firms covering the most recent industrial biotechnologies, financial strategies, useful best practices for improving your business, while also identifying trends, threats and opportunities on the horizon general attendee Conference attendees will hear new technologies and unique perspectives on building the biobased economy, providing insights into the latest business developments

Business Development Insight

  • Conference attendees will hear new technologies and unique perspectives on building the biobased economy, providing insights into the latest business developments 
     

GreenTech Investor Sessions Presenting Companies 

Monday, July 24  

8:30 am – 8:45 am        
BOSK Bioproducts 

BOSK Bioproducts was created in 2016 to commercialize its new technology (patent pending) and the biopolymer (PHA) that it produces. This PHA is produced by fermentation of Pulp and Paper mills waste. It is 100% biodegradable, compostable and non-toxic. BOSK uses natural strains (no GMO) and no solvents for extraction/purification. Their main advantage as compared to competition is lower production cost (low cost of carbon source and energy). BOSK’s Bioproducts mission is to commercialize biosourced and compostable finished products based on our proprietary PHA, through industrial partners reproducing Value Chain in plastic industry.

8:50 am – 9:05 am 
DMC Biotechnologies, Inc.  

DMC is leading the low cost sustainable transformation of multiple product markets. Their novel, patent-pending technology for rapid engineering of robust microbial hosts enables the production of a broad diversity of specialty chemicals, flavors, fragrances, neutracueticals, natural products, pharmaceuticals, and APIs. Deployment of their Synthetic Metabolic Valve (SMV) technology dramatically reduces the cost and development timeline from discovery to commercial performance. Their ultra low cost development will democratize metabolic engineering efforts, creating a multitude of commercially viable bioprocesses and delivering sustainable routes to both new and existing products. 

9:10 am – 9:25 am 
DEINOVE  
DEINOVE is a biotech company that discovers, develops and produces compounds with industrial value from rare microorganisms, for the healthcare, nutrition and cosmetics markets. These innovative production methods represent a sustainable and competitive alternative. For this, DEINOVE relies on two key assets: a unique strain bank with 6,000 rare bacteria that have not yet been exploited, mainly of the Deinococcus genus; and a genetic, metabolic and fermentation engineering platform that enables them to customize these natural micro-factories, transforming them into new industry standards. Its main compounds in development are carotenoids (antioxidants/coloring agents - the company aims to be able to sell the first batches of target compounds by 2018) and novel antibiotics (a first lead is currently undergoing optimization and preclinical studies). 

9:30 am – 10:10 am 
Investor Panel  
The investor panel is comprised of an international group of leading investors who will discuss investment opportunities and trends in GreenTech.

10:35 am – 10:50 am 
S2G BioChemicals Inc. 

S2G Biochem is a global-leading chemical conversion company that is galvanizing a new era of refining for a wide variety products we use everyday.  They build, unlocking the simple sugars from the natural environment to help create sustainable consumer and industrial products. They produce high-value chemicals from low-cost renewable byproducts of the forest products, agricultural and biofuel industries. S2G Biochem will help shift the industrial chemical industry from its traditional dependence on fossil fuels to a sustainable future based on renewable organic feedstocks.

10:55 am – 11:10 am 
Prospect Bio 
Based in Palo Alto, CA, Prospect Bio’s unique metagenomic approach to sourcing naturally found biosensors delivers custom biosensors quickly and cost effectively. Prospect biosensors greatly accelerate customer R&D timelines and expand screening capabilities. In this way, Prospect Bio enables the use of synthetic biology in diverse industries from flavor and fragrances to agriculture to nutrition. 

11:15am – 11:30 am 
Lygos, Inc. 

Lygos employs cutting edge synthetic biology techniques to generate microbial catalysts to convert agricultural feedstocks into fine and commodity chemicals. Their robust high throughput screening and strain construction facilitates the rapid optimization of pathways to convert cheap and renewable feedstock to high value chemicals.

1:45 pm – 2:00 pm 
Mercurius Biorefining, Inc.
 
Mercurius Biofuels was founded in 2009 and later incorporated into Mercurius Biorefining. Their mission is to produce a wide range of biomaterials, with a focus on drop-in biofuels for aviation and diesel engines. In addition, the process generates valuable by-products such as FDCA, a monomer which can be further used in bioplatics. The patented REACH process (Renewable Acid-hydrolysis Condensation Hydrotreating) is a novel application of proven technologies, and allows for divergent product streams using raw, cellulosic (and hemi-cellulosic) non-food waste & residues. Feedstock sources include municipalities (MSW), forestry and agriculture.

2:05 pm – 2:20 pm     
Kalion, Inc.

Kalion is an early stage industrial biotech company focused on providing low-cost access to glucaric acid and S-3-hydroxybutyrolactone (3-HBL) using traditional and green fermentation technology. Glucaric acid and 3-HBL were identified as "Top Value Added Chemicals from Biomass," and multi-billion dollar markets for use of the two chemicals are limited by cost and availability.   Kalion is engaged with academic and industrial partners to develop a wide range of applications to exploit the economic benefits of access to low cost glucaric acid.   

2:25 pm – 2:40pm     
Leaf Resources Ltd

Leaf Resources is one of the world's leading companies in converting plant biomass into fermentable sugars. Their proprietary process for converting biomass-to-functional industrial sugars enable a myriad of downstream technologies for the production of renewable chemicals that will substitute petrochemicals used in manufacturing today. With their project development and continued technical innovation they are building a robust global business centered on renewable carbon containing products to deliver environmental and economic benefits to our shareholders and our planet.  

2:45 pm – 3:00 pm 
Industrial Microbes 

Industrial Microbes is a synthetic biology startup commercializing new processes for methane-based fermentation. Methane is a new feedstock that has the potential to transform the bioeconomy by lowering costs, unlocking new chemical markets, and reducing carbon emissions. Industrial Microbes was launched in 2014 by three founders with experience engineering microbes for commercial-scale chemical production at LS9, an industry leader in the bio-based synthesis of fuels and chemicals. The founders were starting members of the group that developed a commercial strain and process to produce detergent fatty alcohols, a $3 billion global market. The company mission is to expand the palate of feedstocks available for fermentation production, in order to help partners increase margins and expand product lines.

*Qualified investors are defined as institutional, private equity, angel and venture investors with funds on-hand, whose primary activity is direct investment in research and development companies (e.g., hedge fund, mutual fund, or venture fund). Equity research analysts from investment banking institutions and buy-side analysts also qualify as investors. Qualified investors receive a reduced registration fee to attend the entire conference.